This research develops non-parametric methodology for sequential monitoring of paired time-to-event data when comparing years of life saved, or years where any unpleasant outcome is delayed, is of interest. The recommended family of test statistics uses integrated di erences in survival estimates that are available during the study period, where adjustments are made for dependence in the survival and censoring outcomes under comparison. In the context of paired censored survival data, the joint asymptotic closed form distribution of these sequentially monitored test statistics is developed and shown to have a dependent increments structure. Simulations verifying nice operating characteristics of the proposed monitoring methods also reveal consequences of ignoring an underlying paired data structure in terms of size and power properties. A motivating example is also presented via the Early Treatment Diabetic Retinopathy Study, which did not have methods available for sequentially monitoring paired censored survival data at the time.
INTRODUCTION
Paired designs have historically been utilized to minimize extraneous sources of variability in making treatment comparisons. Advantages of this study design in positively correlated pairs include increased power to detect treatment di erences as compared to similarly sized studies on independent treatment groups. Conversely, if a particular power is desired, paired designs usually achieve the desired power with a smaller required sample size than designs involving independent treatment groups. When paired designs are based on time-to-event endpoints that are available very quickly, tests such as Wilcoxon's signed-rank test or a standard paired t-test may be employed in an analysis. In cases where the endpoint of interest takes longer to observe, counterparts to the paired t-test that can accommodate right censoring are desirable.
A counterpart to the two-sample t-test for independent groups that has received attention in the censored data setting is the years of life saved (YLS) test, which has been independently developed for the group sequential setting by Murray and Tsiatis [1] and Li [2] , after its initial discussion by Pepe and Fleming [3] . These tests compare integrated Kaplan-Meier survival estimates, sometimes weighted, during the study period. Murray [4] recently extended YLS tests to accommodate paired censored survival data in the case of a single analysis. Since integrated Kaplan-Meier curves correspond to the sample mean in the absence of censoring, YLS tests constructed with correlated Kaplan-Meier curves are the closest relatives to the paired t-test in the censored survival setting. YLS tests have been frequently lauded as an alternative to the logrank (LR) test, particularly attractive when hazards are not proportional in nature, and are straightforward to communicate to audiences with an emphasis in clinical rather than statistical training. For instance, in collaborating with diabetic retinopathy investigators in studying paired censored time to vision loss, YLS methods provide point estimates and conÿdence intervals on the average extended time of vision for eyes on the superior intervention during the study period.
The Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group collected information on severe vision loss in patients suited to this purpose, where severe visual loss was deÿned as visual acuity less than 5=200 at two consecutive visits. This group enrolled 3711 patients with mild-to-severe non-proliferative or early proliferative diabetic retinopathy in both eyes from April 1980 to July 1985 [5; 6] . One eye of each patient was randomized to early photocoagulation and the other to deferral of photocoagulation until such time when high-risk proliferative retinopathy was detected. Because patients were recruited and followed in the ETDRS over a period of nine years, ethical considerations required periodic monitoring of accumulating time-to-event data in order to ensure timely detection of treatment beneÿts or detriments among the study participants. The ETDRS therefore would prepare reports at least twice a year for a Data Monitoring Committee that would subsequently use the information in determining whether the trial should end early or be continued. Hence appropriate YLS analysis methods require correct handling of censoring, pairing and sequential monitoring issues with respect to the data. Principles of group sequential monitoring outlined by Pocock [7] , O'Brien and Fleming [8] and Lan and DeMets [9] set the standard for extending YLS methods to paired censored survival data monitored in the ETDRS trial.
So far little group sequential methodology has been developed for use in the paired censored survival data setting as in the ETDRS. Chang et al. [10] considered sequential methods for frailty models assuming common pair entry times. Murray [11] developed methods for group sequential monitoring of paired weighted LR tests that allowed entry times to vary within the correlated pairs. Other authors have studied sequential designs for independent treatment groups where multiple correlated censored survival outcomes are monitored. For instance, Lin [12] devised a non-parametric weighted linear rank statistic for monitoring correlated non-identically distributed outcome types subject to censoring across two independent groups, while Muñoz et al. [13] proposed parametric models for sequentially monitoring correlated pairs of similar outcome types subject to censoring across independent groups. However, group sequential development of the YLS method for matched pair experiments with censored data is currently unavailable for studies designed similarly to the ETDRS.
This research makes available methods for sequential analysis of paired YLS tests. As in all group sequential methods, the key to the sequential monitoring lies in understanding the joint distribution of the repeated statistical tests. Section 2 describes the paired YLS test in the case where a single analysis takes place and the joint distribution of these tests at di erent analysis times. Results from this section reveal that the dependent nature of the paired outcomes belies any possibility of an independent increments covariance structure of the repeated tests. Indications for how to use the joint distribution to produce stopping boundaries are also given in this section. Simulations verifying the operating characteristics of the recommended sequential monitoring procedure are given in Section 3. Comparisons are made with sequential monitoring procedures that do not account for the dependent structure of the paired censored time-to-event outcomes. In Section 4, an example relating to the ETDRS study is given. A discussion follows in Section 5.
JOINT DISTRIBUTION OF PAIRED YLS STATISTICS
To understand concepts relating to sequential theory in the setting of dependent time-to-event outcomes being compared across time, an explanation of notation is required. Let g = 1; 2 denote treatment group and i = 1; : : : ; n denote either an individual who experiences both treatments, as in the previously mentioned ETDRS example, or potentially a matched pair whose members are randomized to receive opposing treatment regimens, as in a study on siblings. These n individuals or n matched pairs enter the trial at times E gi , for i = 1; : : : ; n and g = 1; 2 during the accrual period. In many cases E 1i = E 2i , referring to the single entry time of an individual denoted by i, otherwise E 1i and E 2i denote potentially di erent entry times. Entry times are assumed to be identically distributed within treatment group g with E g1i1 independent of E g2i2 for i 1 = i 2 . Each individual or matched pair denoted by i has two correlated survival times T gi ; g= 1; 2 measured from the time of entry. For instance in the ETDRS, T 1i and T 2i measure time from randomization to an objective measure of severe vision loss for eyes randomized to deferred and early photocoagulation, respectively, within an individual. Timeto-event outcomes for each individual or matched pair that have not occurred prior to the time of analysis are censored. For instance, if the data were analysed at calendar time t, one would censor outcomes where T gi ¿t − E gi . The notation V gi , g = 1; 2, i = 1; : : : ; n, will be used to refer to the potential censoring times due to random loss to follow-up. Aside from potential dependence allowed between E 1i and E 2i , between T 1i and T 2i , and between V 1i and V 2i , it is assumed that E gi , V gi and T gi are independent for all g = 1; 2 and i = 1; : : : ; n. If the data were analysed at calendar time t, then the observable random variables for treatment group g would be {X gi (t); gi (t)}, for all i = 1; : : : ; n such that E gi 6t, where X gi (t) = min(T gi ; V gi ; t − E gi ) is the observed time on study at analysis time t and gi (t) = I {T gi 6min(t − E gi ; V gi )} denotes the failure indicator at calendar time t. Indices referring to calendar time measured from the start of the study, and indices referring to time measured from a patient's entry into the study will frequently be used in combination. Hence note that the index 't' will index calendar time of an analysis, and the index 'x' will index time from entry into the study, commonly referred to as study time.
Deÿne the total sample size enrolled at calendar time t in group g as n g (t) = n i=1 I (E gi 6t). In order to keep track of the number of correlated entered pairs across treatment groups g 1 ; g 2 and calendar times t 1 ; t 2 we deÿne n g1g2 (t 1 ; t 2 ) = n i=1 I (E g1i 6t 1 ; E g2i 6t 2 ). Note that when pairs of dependent outcomes are attributed to an individual, one will often have n 1 (t) = n 2 (t) = n 12 (t; t). If at the ÿnal analysis time all treatment pairs have been entered, one will have n 1 (t) = n 2 (t) = n 12 (t; t) = n. However this method also allows for the case where some individual pair members remain unentered at the time of the ÿnal analysis, as long as the number of complete pairs entered is approaching inÿnity.
For each treatment group g and calendar analysis time t, deÿne the number of individuals at risk at study time x as Y g (t; x) = J (t; x) = 0 otherwise. Let n * (t) = n 1 (t)n 2 (t)={n 1 (t) + n 2 (t)}. At each analysis time t, consider a paired YLS test
whereŜ g (t; x) is the Kaplan-Meier survival estimate for the true survival at study time x; S g (x), using information available for all individuals entered in group g at analysis time t, regardless of whether their correlated counterpart has entered the study or not. The remainder of this section describes results on variability of this statistic when it is sequentially monitored and methods for ÿnding statistical signiÿcance cutpoints that will protect the overall type I error rate of the trial. Some readers may choose to avoid notational deÿnitions relating to the covariance structure of the sequentially monitored statistics by skipping ahead to the last paragraph of this section. The variability of this statistic at a single analysis time requires notation relating to joint and conditional hazards of the correlated endpoints. It will later be convenient to allow for the correlated random variables of interest in the following deÿnitions to have di erent amounts of calendar time follow-up according to their use at analysis times t 1 and t 2 . Deÿnitions appropriate for a single analysis time would use t 1 = t 2 = t. Also, to reduce notation, the index i referring to the individual or matched pair will be suppressed in the following deÿnitions of joint and conditional terms. Deÿne g1g2 {(t 1 ; x 1 ); (t 2 ; x 2 )} = lim x1; x2→0 P(
to be a joint hazard function for the correlated endpoints in treatment groups g 1 = g 2 at study times x 1 and x 2 where outcomes related to g 1 are subject to data available at calendar time t 1 and outcomes related to g 2 are subject to data available at calendar time t 2 , (06x 1 6t 1 ; 06x 2 6t 2 ). Also deÿne the conditional hazard function g1|g2 {(t 1 ; x 1 )|(t 2 ; x 2 )} = lim x1→0 P(x 1 6X g1 (t 1 )¡ x 1 + x 1 ; g1 (t 1 ) = 1|X g1 (t 1 )¿x 1 ; X g2 (t 2 )¿x 2 )= x 1 , which may be interpreted as the hazard of failure for treatment group g 1 at study time x 1 where again outcomes related to g 1 are subject to data available at calendar time t 1 and outcomes related to g 2 are subject to data available at calendar time t 2 and where the risk set is restricted to those patients with X g1 (t 1 )¿x 1 and X g2 (t 2 )¿x 2 , (06x 1 6t 1 ; 06x 2 6t 2 ). Also deÿne the marginal hazard for treatment group g at calendar time t and study time x, 06x6t, to be g (t; x) = lim x→0 P(x6X g (t)¡x + x; g (t) = 1|X g (t)¿x)=( x), which under the random censorship assumptions previously described reduces to the true hazard of T g , g (x), and is not dependent on analysis time t. Let
Also, to reduce notation, deÿne A(t; x) = ∞ x p(t; u)S(u) du, where p(t; x) = I [P{X 1 (t)¿x} × P{X 2 (t)¿x}¿0]. In the case where a single analysis occurs at analysis time t, the asymptotic variance of T(t) is
where g (t) = lim {n1(t); n2(t)→∞} n g (t)={n 1 (t) + n 2 (t)} is the probability at calendar time t of being entered into treatment group g with estimateˆ g (t) = n g (t)={n 1 (t) + n 2 (t)} and Â(t) = lim {n12(t; t)→∞} 2n 12 (t; t)={n 1 (t)+n 2 (t)} is the sampling proportion of dependent observations in the two treatment groups at calendar time t with estimateÂ(t) = 2n 12 (t; t)={n 1 (t) + n 2 (t)}. Pooled and unpooled estimation procedures for 2 (t) are given in the Appendix. In many cases where individuals are entered into the study and immediately given the two competing treatments as in the ETDRS example, g (t) = 0:5 and Â(t) = 1. In cases where matched pairs have di erent random entry times into the trial there may be a subset of individual pair members with an unentered counterpart at the time of analysis t and Â(t) can be interpreted as a ecting the degree to which the ÿnal term of 2 (t) deviates from the usual variance under independent treatment groups. Also note that when censored time-to-event pairs are truly independent in nature, 2 (t) will correspond to the usual variance described by Pepe and Fleming under independent treatment groups.
Further notation is required to describe the covariance of T(t 1 ) and T(t 2 ), where without loss of generality this paper will assume t 1 6t 2 . Let H g (t; x) = P(E g 6t − x; V g ¿x|E g 6t) be the censoring survival distribution among individuals in treatment group g entered by calendar time t. Deÿne g (t 1 |t 2 ) = lim {ng(t1)→∞} n g (t 1 )=n g (t 2 ) as the probability of entry in group g by t 1 given entry in group g by t 2 with estimateˆ g (t 1 |t 2 )=n g (t 1 )=n g (t 2 ). Let Â g1g2 (t 1 ; t 2 ) = lim {ng 1 g 2 (t1; t2)→∞} 2n g1g2 (t 1 ; t 2 )={n g1 (t 1 ) + n g2 (t 2 )} be the sampling proportion of dependent observations in treatment group g 1 at analysis time t 1 and treatment group g 2 at analysis time t 2 with estimateÂ g1g2 (t 1 ; t 2 ) = 2n g1g2 (t 1 ; t 2 )={n g1 (t 1 )+n g2 (t 2 )}. Let g1g2 (t 1 ; t 2 )= lim {ng1(t1); ng2(t2)→∞} n g1 (t 1 )={n g1 (t 1 ) + n g2 (t 2 )} be the sampling proportion of observations available at analysis time t 1 from treatment group g 1 among the total number of observations available for treatment group g 1 at analysis time t 1 and for treatment group g 2 at analysis time t 2 with estimateˆ g1g2 (t 1 ; t 2 ) = n g1 (t 1 )={n g1 (t 1 ) + n g2 (t 2 )}. Deÿne g1g2 (t 1 ; t 2 
). An estimator, g1g2 (t 1 ; t 2 ), for g1g2 (t 1 ; t 2 ) is constructed easily from the estimates of its components. Finally, the covariance of T(t 1 ) and T(t 2 ) is as shown in the Appendix where pooled and unpooled estimates for (t 1 ; t 2 ) are also located. Note that when n g (t 1 ) = n g (t 2 ) = n gg (t 1 ; t 2 ); gg (t 1 ; t 2 ) reduces to 3−g (t 1 ) = 3−g (t 2 ) and g (t 1 |t 2 ) becomes one. If in addition t 1 = t 2 = t, (t 1 ; t 2 ) reduces to 2 (t). In general the covariance between T(t 1 ) and T(t 2 ) does not reduce to the variance at the earlier interim analysis. The joint distribution of T(t 1 ) and T(t 2 ) does not have an independent increments structure. This di ers somewhat from the independent treatment group case, where deÿning J (t; x) terms to be equivalent at all analysis times t would result in an independent increments structure.
To calculate sequential boundaries in this non-independent increments case, one may use Monte Carlo numerical integration techniques in relation to the joint distribution of the test statistics at the various analysis times. First a suitable spending function is selected such as the O'Brien-Fleming (OF) styled spending function OF (v j ) = 2 − 2 (z =2 = √ v j ), where v j corresponds to some surrogate for the proportion of information collected at the jth interim analysis time. The surrogate for the proportion of information collected may be chosen to re ect the percentage of calendar time elapsed toward the planned length of the study or may be chosen as the percentage of observed events at the analysis time of those required by the end of the study to achieve the designed power. Both of these choices would be known at the design stage of a clinical trial and either would be appropriate in terms of protecting type I error of the trial. Next the covariance structure between the current and all previous T(t) test statistics calculated during the course of the trial using the observed data is estimated. At the jth analysis time boundary cutpoints, c 1 ; : : : ; c j , must be chosen so that P(|T(t 1 )|¡c 1 ; : : : ; |T(t j−1 )|¡c j−1 ; |T(t j )|¿c j ) = P(|T(t j )|¿c j |T(t 1 )|¡c 1 ; : : : ; |T(t j−1 )|¡c j−1 )P(|T(t 1 )|¡c 1 ; : : : ; |T(t j−1 )|¡c j−1 )
the type I error to be spent at the jth analysis time. Multivariate mean zero normal random variables with the observed covariance structure are simulated and used to estimate appropriate cut-o points for the statistics at the di erent analysis times. The process is recursive in nature. For instance after determining c 1 ; : : : ; c j−1 , one may easily use the multivariate normal replicates to estimate P(|T(t 1 )|¡c 1 ; : : : ; |T(t j−1 )|¡c j−1 ) and the boundary c j may be found by considering the tails of the marginal distribution corresponding to the jth analysis time among multivariate replicates that did not surpass cutpoints at previous analysis times. An example using ETDRS data in Section 4 provides additional instruction on how these simulated boundaries are constructed.
SIMULATION RESULTS
In order to verify size of the proposed sequential monitoring strategy, 1000 Monte Carlo simulations under the null hypothesis of no treatment di erence were conducted using 150 failure time pairs generated from the bivariate log-normal distribution, where correlations examined between the two failure times on the log scale were {0 per cent, 30 per cent, 60 per cent, 90 per cent}. Log scale means and variances were 0.3 and 1, respectively, for each of the two treatment group failure times. for pair members were simulated using the Uniform(0, 1) distribution. Interim analyses were conducted at years 3, 4 and 5 using calendar time as a surrogate for statistical information in the O'Brien-Fleming spending function with an overall type I error of 0.05. Observed paired and unpaired YLS test sizes in increasing order of correlation using pooled estimates for variances and covariances are located in the upper panel of Table I . Similar results were observed using unpooled variance and covariance estimates. Sizes corresponding to the paired tests have appropriate type I error levels for all degrees of correlation, while unpaired tests become increasingly conservative as underlying correlation in the survival times grows. Entrytime correlation appears to have little bearing on the performance of the sequentially monitored tests. To study operating characteristics under an alternative hypothesis, 150 failure time pairs were generated from the bivariate log-normal distribution with log scale means of (0.5, 0.3) with variability parameters unchanged from the simulations described above. Results for paired and unpaired tests are located in the lower panel of Table I using the O'Brien-Fleming spending function and pooled variance and covariance estimates. Note that in all simulations conducted under the alternative hypothesis, the marginal distributions of the two groups under comparison remain unchanged. Monitoring strategies that take into account the paired correlation structure increase in power with growing correlation in survival times for comparable group marginal distributions. In contrast, the usual sequential monitoring strategy that does not take into account dependence between paired survival outcomes loses substantial power as correlation in paired survival times increases. These unattractive power and size results related to unpaired tests are likely an artefact of the two estimated survival curves tending to vary in tandem in the presence of positive correlation and give evidence that accounting for the dependent structure of the data is a crucial step in the group sequential analysis.
EXAMPLE
Recall the Early Treatment Diabetic Retinopathy Study (ETDRS) described in the introduction, which enrolled 3711 patients with mild-to-severe non-proliferative or early proliferative diabetic retinopathy in both eyes and randomized one eye of each patient to early photocoagulation and the other to deferral of photocoagulation until a later time when high-risk proliferative retinopathy was detected. The major endpoint of interest was time to severe visual loss. The Data Monitoring Committee prepared interim reports approximately twice a year using statistical methods of comparison which did not take into account the pairing of eyes on study. The ÿrst interim analysis took place when 50 events had occurred across the two comparison groups. A statistically signiÿcant result during monitoring was deÿned as a test statistic with corresponding p-value less than 0.01. The Data Monitoring Committee, which did not have access to methodology for sequentially monitoring paired censored survival data, nevertheless recognized the statistical issues relating to the correlated structure of the data. Some exploratory analysis on their part suggested 'that not taking pairing into account led to conservative tests (reference [5] , p. 749)'. However, with their large sample size they were still able to detect a longer time to sight deterioration with early photocoagulation.
As an example of the proposed analysis methods which take into account the natural pairing of the data, the ETDRS study is revisited. To make this example more interesting, the analysis is restricted to those 999 patients (1998 eyes) who entered the study prior to 15 February 1983 and who were simultaneously taking a placebo pill as part of a separate randomization, reducing by nearly 75 per cent the sample size of the original ETDRS study. Following the example of the ETDRS study, the ÿrst analysis will take place using data that would have been available on 8 April 1985, when 50 events had been observed, and continue twice a year until 8 April 1989 for a total of nine interim analyses. However, this example will use a more conservative type I error than the original study. After nine analyses, the following strategy will have merely a 1 per cent type I error overall instead of the originally planned 1 per cent error per interim analysis. An O'Brien-Fleming spending function will be employed where the ratio of deaths observed by the interim analysis compared to the total deaths on 8 April 1989 is used as a surrogate for the proportion of information collected. Note that in a prospective clinical trial, one would estimate the total number of deaths required for a well powered design at the last analysis time in this computation.
Results in Table II include interim analysis number, type I error spent at each analysis time, observed integrated hazard di erences corresponding to a LR test analysis approach, the average extended days of sight observed in the early photocoagulation treatment arm during the study period ({n * (t)} −1=2 T) and sequential boundaries corresponding to paired and unpaired YLS and LR tests at the nine analysis times. Paired and unpaired LR boundaries were calculated as in Murray [11] . To determine appropriate sequential boundary cutpoints for the YLS analyses, Monte Carlo numerical integration strategies were employed in relation to the joint distribution of the test statistics at the nine interim analyses. First a covariance matrix corresponding to these observed integrated survival di erences was constructed using pooled formulae outlined in the Appendix. Multivariate mean zero normal random variables with the observed covariance structure were then simulated. At the jth analysis time, j = 1; : : : ; 9, boundary cutpoints c 1 ; : : : ; c j were chosen so that P(|T(t 1 )|¡c 1 ; : : : ; |T(t j−1 )|¡c j−1 ; |T(t j )|¿c j ) was equal to the type I error to be spent at the jth analysis time. Speciÿcally, the ÿrst cutpoint, c 1 , identiÿes the value which gives 2:85 × 10 −5 type I error in the tails of the marginal normal distribution corresponding to the ÿrst analysis time, so that P(|T(t 1 )|¿c 1 ) = 2:85 × 10 −5 . The Monte Carlo results gave c 1 = 31:35 when monitoring with the paired YLS statistic. The second cutpoint, c 2 , was chosen so that P(|T(t 1 )|¡31:35; |T(t 2 )|¿c 2 ) = P(|T(t 2 )|¿c 2 |T(t 1 )| ¡31:35)P(|T(t 1 )|¡31:35) was equal to 1:42 × 10 −4 . Hence the value of c 2 = 30:04 was found by considering the tails of the marginal normal distribution corresponding to the second analysis time in multivariate normal replicates that did not surpass the ÿrst cutpoint at the ÿrst analysis time in combination with the Monte Carlo estimate of P(|T(t 1 )|¡31:35). Similarly the value of c 3 = 36:00 was determined by considering the tails of the marginal normal distribution corresponding to the third analysis time among multivariate normal replicates that did not surpass cutpoints at previous analysis times in combination with the Monte Carlo estimate of P(|T(t 1 )|¡31:35; |T(t 2 )|¡30:04), and so on. In studying the various sequential boundaries in Table II , the null hypothesis was rejected at the 0.01 level at the eighth analysis time using either the paired YLS or the paired LR test. At this analysis 52.95 extra days of sight were observed on average in the ÿrst 8.47 years of observation in the early photocoagulation group (95 per cent conÿdence interval 19.36, 86.54 extra days of sight), although this estimate and corresponding conÿdence interval are slightly in ated due to the nature of the sequential stopping rule. Neither of the monitoring strategies that ignore the correlated nature of the pairs was able to achieve statistical signiÿcance in this smaller data set.
DISCUSSION
This research presents closed form asymptotic distributions of years of life saved tests for use with paired censored survival data and makes available new group sequential monitoring procedures related to these statistics. In studying the joint structure of the recommended test statistics computed over time, asymptotic closed form variances and covariances of the test statistics are provided. Based on these closed form quantities, pooled and unpooled variance and covariance estimates are proposed that, in combination with the recommended monitoring procedure, perform very well towards the goal of protecting the overall type I error whether one or multiple analyses are performed.
Methods in this research can also easily accommodate tests based on integrated weighted di erences in survival by including these weighting functions within the J (t; x) component of the tests described herein. Theoretical development remains the same as long as the weighting function converges in probability at all study times, x. If weighting is desired to capture early survival di erences with higher probability, for instance, a ÿxed weighting function with higher weights at the earlier study times could capture this e ectively. Users are cautioned about selecting weights that depend on the censoring mechanism, since at each analysis time the degree of censoring will change and a ect the interpretation of the test statistic. This would result in the trial design depending on changing alternatives across analysis times, t. The interpretation issue cited here does not play a role in the sequential analyses of weighted LR style tests, since weights in that setting are designed to emphasize areas where proportional hazards are measured more accurately. Hence the interpretation of sequentially computed weighted logrank statistics remains similar in the case of proportional hazards as the weights change from analysis to analysis.
Currently many clinical trials that monitor paired survival endpoints, such as the ETDRS, employ study designs based on independent samples. Also, because methods based on independent samples are readily available for monitoring purposes, the temptation is to use already available methods while acknowledging their conservativeness. This research demonstrates that taking advantage of the positive correlation structure in the paired outcomes gives large beneÿts in terms of both type I error and power. Simulations in Section 3 also indicate that for paired censored survival data structures, power under the alternative hypothesis might not even match the power aimed for in design when methods for independent samples are used both in design and analysis stages of clinical research. This is a cause for concern in current practice with this data structure that the proposed methods eliminate very nicely.
APPENDIX

A1. Covariance of T(t 1 ) and T(t 2 )
For each treatment group g and calendar analysis time t, deÿne the number of events occurring no later than study time x as N g (t; x) = n i=1 I {X gi (t)6x; gi (t) = 1} for 06x6t and let M g (t; x) = N g (t; x) − x 0 g (u)Y g (t; u) du. Consider T(t), which after an application of the martingale central limit theorem is asymptotically equivalent in distribution to Z 1 (t) − Z 2 (t) under the null hypothesis of no treatment di erence, where
The covariance of interest, cov{T(t 1 ); T(t 2 )}; becomes
A result from Murray and Tsiatis [1] gives that Z g (t 1 ) and Z g (t 2 ) are asymptotically jointly normal mean zero random variables with cov{Z g (t 1 );
If our treatment groups were independent, then this last result would give us all needed information to identify the joint distribution of T(t 1 ) and T(t 2 ). In fact, under the assumption of independent treatment groups and J (t 1 ; u) = J (t 2 ; u) for all t 1 ; t 2 one would have an independent increments setting. However, one also needs to identify cov{Z g1 (t 1 ); Z g2 (t 2 )} for g 1 = g 2 . In this case an application of the multivariate central limit theorem gives the result cov{Z g1 (t 1 ); Z g2 (t 2 )} = g1g2 (t 1 ; t 2 )
becomes the asymptotic covariance for T(t 1 ) and T(t 2 ). Taking t 1 = t 2 = t provides 2 (t), the variance of T(t) in the case of a single analysis as found in Murray [4] .
A2. Estimation of variances and covariances in this paper
All asymptotic closed form variance and covariance terms in this paper are easily estimated. However, additional notation is required. First note that in estimating joint and conditional quantities in relation to group g 1 at time t 1 and group g 2 at time t 2 , attention is restricted to those k = 1; : : : ; n g1g2 (t 1 ; t 2 ) correlated pairs where study entry has occurred for both members of the pair at their respective analysis times. In estimating marginal quantities in relation to group g at time t, all individual pair members entered into group g before time t will be considered regardless of whether their correlated counterpart has been entered into the study.
Let Y g1g2 {(t 1 ; x 1 ); (t 2 ; x 2 )} = ng 1 g 2 (t1; t2) k=1 I (X g1k (t 1 )¿x 1 ; X g2k (t 2 )¿x 2 ) count the number of correlated pairs where the pair member in group g 1 at analysis time t 1 is still at risk at study time x 1 and the pair member in group g 2 at analysis time t 2 is still at risk at study time x 2 . Also, let dN g1g2 {(t 1 ; x 1 ); (t 2 ; x 2 )} = ng 1 g 2 (t1; t2) k=1 I (x 1 6X g1k (t 1 )¡x 1 + x 1 ; x 2 6X g2k (t 2 )¡ x 2 + x 2 ; g1k (t 1 ) = 1; g2k (t 2 ) = 1) count the number of correlated pairs where the pair member in group g 1 at analysis time t 1 fails at study time x 1 and the pair member in group g 2 at analysis time t 2 fails at study time x 2 . Let dN g1|g2 {(t 1 ; x 1 )|(t 2 ; x 2 )} = ng 1 g 2 (t1; t2) k=1 I (x 1 6X g1k (t 1 ) ¡x 1 + x 1 ; X g2k (t 2 )¿x 2 ; g1k (t 1 ) = 1) count the number of correlated pairs where the pair member in group g 1 at analysis time t 1 had been at risk until failing at study time x 1 and the pair member in group g 2 at analysis time t 2 remains at risk at study time x 2 . An unpooled estimate for G g1g2 {(t 1 ; x 1 ); (t 2 ; x 2 )} dx 1 
